Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.

Edo Kaluski,Gad Cotter,Marina Leitman,Olga Milo-Cotter,Ricardo Krakover,Isaac Kobrin,Tina Moriconi,Maurizio Rainisio,Avraham Caspi,Leonardo Reizin,Reuven Zimlichman,Zvi Vered

Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.

2008

Edo Kaluski
Gad Cotter
Marina Leitman
Olga Milo-Cotter
Ricardo Krakover
Isaac Kobrin
Tina Moriconi
Maurizio Rainisio
Avraham Caspi
Leonardo Reizin
Reuven Zimlichman
Zvi Vered

Objective: Toevaluate the effects of bosentan on echo-derived hemodynamic measurements, and clinical variables in symptomatic heart failure (HF) patients. Method:

Keywords:

Bosentan
Randomized controlled trial
Hemodynamics
Pulmonary hypertension
Internal medicine
Cardiology
Heart failure
Ejection fraction
Blood pressure
Cardiac index
Medicine
Anesthesia
dose optimization
hemodynamic effects
Severity of illness
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations